<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02741739</url>
  </required_header>
  <id_info>
    <org_study_id>R1033-HV-1503</org_study_id>
    <nct_id>NCT02741739</nct_id>
  </id_info>
  <brief_title>Study of the Blood Concentrations of Two Formulations of REGN1033 in Healthy Subjects</brief_title>
  <official_title>A Randomized, Open-Label, Parallel Group Study of the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of REGN1033 Produced From Two Different Cell Lines in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective: Determine blood concentrations of two formulations of REGN1033.

      Secondary Objective: Assess safety and tolerability of REGN1033.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum REGN1033 concentration-time curve (AUC)</measure>
    <time_frame>Pre-dose to day 57</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak REGN1033 concentration (Cmax)</measure>
    <time_frame>Pre-dose to day 57</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent adverse events (TEAEs) from baseline to the end of the study</measure>
    <time_frame>Day 1 to end of study (Day 57)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence or absence of anti-drug antibody (ADA)</measure>
    <time_frame>Day 1 to end of study (Day 57)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Reference Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>REGN1033 Reference Formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>REGN1033 Test Formulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN1033</intervention_name>
    <arm_group_label>Reference Drug</arm_group_label>
    <arm_group_label>Test Drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Healthy males and females (not of childbearing potential) between the ages of 18 and
             65 years

          2. Body weight between 50.0 kg and 95.0 kg

          3. Willing and able to comply with clinic visits and study-related procedures

          4. Provide signed informed consent

        Key Exclusion Criteria:

          1. Donation or loss of approximately 400 mL or more of blood within 8 weeks prior to
             dosing, or plasma up to 14 days prior to dosing

          2. Hemoglobin not within normal limits

          3. Positive drug and alcohol screen test results at screening visits 1 and 2

          4. Low or elevated blood pressure and/or heart rate after 3 minutes resting in the seated
             position:

          5. Recent use (within 3 months prior to screening) of androgenic steroids

          6. Participation in any clinical research study that evaluated another investigational
             drug or therapy within 30 days or at least 5 half-lives, whichever is longer, of the
             investigational drug, prior to the screening visit

          7. Previous exposure to any biological therapeutic agent, except vaccines

          8. Known sensitivity to tamoxifen, doxycycline, or similar compounds (ie, tetracyclines)

          9. Pregnant or breastfeeding women, and women of childbearing potential

         10. Sexually active men who are unwilling to practice adequate contraception during the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2016</study_first_submitted>
  <study_first_submitted_qc>April 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2016</study_first_posted>
  <last_update_submitted>October 13, 2016</last_update_submitted>
  <last_update_submitted_qc>October 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug concentration</keyword>
  <keyword>REGN1033</keyword>
  <keyword>blood</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

